Qtern (Dapagliflozin/Saxagliptin HCl) Patent Expiration, LOE Window & CMS Spending

Qtern (Dapagliflozin/Saxagliptin HCl) by AstraZeneca: FDA Orange Book core substance LOE 2030-06-16, 2 AB generics, $1.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN209091 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-06-16
Last Listed Patent or Exclusivity Date2030-06-16
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$86K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.